Therapeutic Potential of Sea Cucumber-Derived Bioactives in the Prevention and Management of Brain-Related Disorders: A Comprehensive Review.

IF 5.4 2区医学 Q1 CHEMISTRY, MEDICINAL

Marine Drugs Pub Date : 2025-07-30 DOI:10.3390/md23080310

Purnima Rani Debi, Hrishika Barua, Mirja Kaizer Ahmmed, Shuva Bhowmik

{"title":"Therapeutic Potential of Sea Cucumber-Derived Bioactives in the Prevention and Management of Brain-Related Disorders: A Comprehensive Review.","authors":"Purnima Rani Debi, Hrishika Barua, Mirja Kaizer Ahmmed, Shuva Bhowmik","doi":"10.3390/md23080310","DOIUrl":null,"url":null,"abstract":"<p><p>The popularity of bioactive compounds extracted from sea cucumbers is growing due to their wide application in the pharmaceutical industry, particularly in the development of drugs for neurological disorders. Different types of compounds, such as saponins, phenolic compounds, cerebrosides, and glucocerebrosides, are being studied intensively for their efficacy in assessing the treatment of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and brain tumors, among others. Positive results have been observed in the upregulation in the content of p-CREB, p-PL3K, BDNF, SOD, and MDA. Furthermore, the neuroprotective mechanism of the compounds against Alzheimer's disease revealed that suppressing the phosphorylation of tau protein by the PI3K/Akt/GSK3β pathway leads to improved synaptic plasticity and reduced nerve fiber tangles. This comprehensive review explores recent findings on the therapeutic potential of sea cucumber bioactives in the treatment of brain-related disorders.</p>","PeriodicalId":18222,"journal":{"name":"Marine Drugs","volume":"23 8","pages":""},"PeriodicalIF":5.4000,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12387399/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Marine Drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/md23080310","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

The popularity of bioactive compounds extracted from sea cucumbers is growing due to their wide application in the pharmaceutical industry, particularly in the development of drugs for neurological disorders. Different types of compounds, such as saponins, phenolic compounds, cerebrosides, and glucocerebrosides, are being studied intensively for their efficacy in assessing the treatment of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and brain tumors, among others. Positive results have been observed in the upregulation in the content of p-CREB, p-PL3K, BDNF, SOD, and MDA. Furthermore, the neuroprotective mechanism of the compounds against Alzheimer's disease revealed that suppressing the phosphorylation of tau protein by the PI3K/Akt/GSK3β pathway leads to improved synaptic plasticity and reduced nerve fiber tangles. This comprehensive review explores recent findings on the therapeutic potential of sea cucumber bioactives in the treatment of brain-related disorders.

Abstract Image

查看原文本刊更多论文

海参衍生生物活性物质在预防和治疗脑相关疾病中的治疗潜力：综述

从海参中提取的生物活性化合物由于其在制药工业中的广泛应用而越来越受欢迎，特别是在神经疾病药物的开发中。不同类型的化合物，如皂苷、酚类化合物、脑苷和糖脑苷，正在深入研究它们在评估神经退行性疾病（包括阿尔茨海默病、帕金森氏病和脑肿瘤等）治疗方面的功效。p-CREB、p-PL3K、BDNF、SOD和MDA含量上调均呈阳性结果。此外，化合物抗阿尔茨海默病的神经保护机制表明，通过PI3K/Akt/GSK3β途径抑制tau蛋白磷酸化可改善突触可塑性，减少神经纤维缠结。本文综述了海参生物活性物质在脑相关疾病治疗方面的研究进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Marine Drugs 医学-医药化学

CiteScore

9.60

自引率

14.80%

发文量

671

审稿时长

1 months

期刊介绍： Marine Drugs (ISSN 1660-3397) publishes reviews, regular research papers and short notes on the research, development and production of drugs from the sea. Our aim is to encourage scientists to publish their experimental and theoretical research in as much detail as possible, particularly synthetic procedures and characterization information for bioactive compounds. There is no restriction on the length of the experimental section.